In 2001, the national AIDS research agency initiated a research programme on the access of patients to anti-AIDS treatments in countries of the South. The programme, "ETAPSUD" proposes, in particular, to discuss the impact of the production of antiretroviral drugs in the South on the access of patients to more affordable anti-AIDS treatments.
In this context, a study was initiated in October 2002 at CSH to assess the methods used by Indian health authorities to check the disturbing increase of the infection among the Indian population. On the one hand, the study proposes to review the public health measures taken by the Indian authorities, while on the other, it examines India's industrial capacity in manufacturing generic antiretroviral drugs. With its voluntarist industrial policy, India has been able to build up a high-performance pharmaceutical industry to increase the country's autonomy in matters of health and to reduce the price of medicines.